<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36851359</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Transient Positive SARS-CoV-2 PCR without Induction of Systemic Immune Responses.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">482</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines11020482</ELocationID><Abstract><AbstractText>SARS-CoV-2 testing is dominated by PCR to guide treatment and individual as well as public health preventive measures. Among 1700 football (soccer) players and staff of the German Bundesliga and Bundesliga 2 who were regularly tested by PCR twice weekly, 98 individuals had a positive PCR (May 2020 to mid-January 2021). A subset of these were retested shortly after the initial positive result. Among those, 11 subjects were identified who only had a transient single positive PCR of low viral load. All individuals were asymptomatic and none developed long COVID. We tested SARS-CoV-2 IgG and IgA as well as SARS-CoV-2 specific CD4 und CD8 positive T cells, and showed that only one out of 11 individuals developed SARS-CoV-2 specific cellular and humoral immunity after the positive PCR, whereas a specific immunity was undetectable in all other individuals. Thus, a single positive PCR might indicate that transient colonization of the upper respiratory tract with SARS-CoV-2 may occur without systemic induction of specific adaptive immunity. Together with test artifacts as another potential reason for a transiently positive test, this finding may favor cautious interpretation of positive PCR results or retesting before initiating intervening treatment or infection control measures in some cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xe4;rtner</LastName><ForeName>Barbara C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Hygiene, Saarland University, Building 43, Kirrberger Stra&#xdf;e, D-66421 Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klemis</LastName><ForeName>Verena</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5636-1273</Identifier><AffiliationInfo><Affiliation>Department of Transplant and Infection Immunology, Saarland University, Building 47/77, Kirrberger Stra&#xdf;e, D-66421 Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Tina</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7929-5283</Identifier><AffiliationInfo><Affiliation>Department of Transplant and Infection Immunology, Saarland University, Building 47/77, Kirrberger Stra&#xdf;e, D-66421 Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sester</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5482-0002</Identifier><AffiliationInfo><Affiliation>Department of Transplant and Infection Immunology, Saarland University, Building 47/77, Kirrberger Stra&#xdf;e, D-66421 Homburg/Saar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Sports and Preventive Medicine, Saarland University, Campus, Geb. B 8.2, D-66123 Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>no grant number</GrantID><Agency>Deutsche Fu&#xdf;ball Liga</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">T cell immunity</Keyword><Keyword MajorTopicYN="N">colonization</Keyword><Keyword MajorTopicYN="N">football</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">mucosal</Keyword></KeywordList><CoiStatement>M.S. received grants and support for attending meetings and/or travel from Novartis, Biotest and Astella and horonaria for lectures from Novartis and Biotest. All other authors have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36851359</ArticleId><ArticleId IdType="pmc">PMC9959254</ArticleId><ArticleId IdType="doi">10.3390/vaccines11020482</ArticleId><ArticleId IdType="pii">vaccines11020482</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bartoletti M., Azap O., Barac A., Bussini L., Ergonul O., Krause R., Pa&#xf1;o-Pardo J.R., Power N.R., Sibani M., Szabo B.G., et al. ESCMID COVID-19 living guidelines: Drug treatment and clinical management. Clin. Microbiol. Infect. 2022;28:222&#x2013;238. doi: 10.1016/j.cmi.2021.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.007</ArticleId><ArticleId IdType="pmc">PMC8606314</ArticleId><ArticleId IdType="pubmed">34823008</ArticleId></ArticleIdList></Reference><Reference><Citation>Talic S., Shah S., Wild H., Gasevic D., Maharaj A., Ademi Z., Li X., Xu W., Mesa-Eguiagaray I., Rostron J., et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: Systematic review and meta-analysis. BMJ. 2021;375:e068302. doi: 10.1136/bmj-2021-068302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068302</ArticleId><ArticleId IdType="pmc">PMC9423125</ArticleId><ArticleId IdType="pubmed">34789505</ArticleId></ArticleIdList></Reference><Reference><Citation>Polisena J., Ospina M., Sanni O., Matenchuk B., Livergant R., Amjad S., Zoric I., Haddad N., Morrison A., Wilson K., et al. Public health measures to reduce the risk of SARS-CoV-2 transmission in Canada during the early days of the COVID-19 pandemic: A scoping review. BMJ Open. 2021;11:e046177. doi: 10.1136/bmjopen-2020-046177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-046177</ArticleId><ArticleId IdType="pmc">PMC7944419</ArticleId><ArticleId IdType="pubmed">33687956</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation  Overview of Public Health and Social Measures in the Context of COVID-1&#x2014;Interim Guidance. 2020.  [(accessed on 18 February 2023)].  Available online:  https://www.who.int/publications/i/item/overview-of-public-health-and-social-measures-in-the-context-of-covid-19.</Citation></Reference><Reference><Citation>Council of the European Union  EU Digital COVID Certificate: How It Works. 2021.  [(accessed on 18 February 2023)].  Available online:  https://www.consilium.europa.eu/en/policies/coronavirus/eu-digital-covid-certificate/</Citation></Reference><Reference><Citation>Loades M.E., Chatburn E., Higson-Sweeney N., Reynolds S., Shafran R., Brigden A., Linney C., McManus M.N., Borwick C., Crawley E. Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19. J. Am. Acad. Child Adolesc. Psychiatry. 2020;59:1218&#x2013;1239.e1213. doi: 10.1016/j.jaac.2020.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaac.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7267797</ArticleId><ArticleId IdType="pubmed">32504808</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard A.J., Bijker E.M. A guide to vaccinology: From basic principles to new developments. Nat. Rev. Immunol. 2021;21:83&#x2013;100. doi: 10.1038/s41577-020-00479-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00479-7</ArticleId><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack D., Gartner B.C., Rossler A., Kimpel J., Donde K., Harzer O., Krutsch W., von Laer D., Meyer T. Prevalence of SARS-CoV-2 IgG antibodies in a large prospective cohort study of elite football players in Germany (May-June 2020): Implications for a testing protocol in asymptomatic individuals and estimation of the rate of undetected cases. Clin. Microbiol. Infect. 2021;27:473.e471&#x2013;473.e474. doi: 10.1016/j.cmi.2020.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.11.033</ArticleId><ArticleId IdType="pmc">PMC7718108</ArticleId><ArticleId IdType="pubmed">33285279</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutscher Fu&#xdf;ball Bund (DFB)  Sports Medicine/Special Match Operations Task Force in Professional Football. 2020.  [(accessed on 18 February 2023)].  Available online:  https://media.dfl.de/sites/3/2020/05/2020-05-01_Sports-Medicine_Special-Match-Operations_Task-Force.pdf.</Citation></Reference><Reference><Citation>Schub D., Klemis V., Schneitler S., Mihm J., Lepper P.M., Wilkens H., Bals R., Eichler H., G&#xe4;rtner B.C., Becker S.L., et al. High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. JCI Insight. 2020;5:e142167. doi: 10.1172/jci.insight.142167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.142167</ArticleId><ArticleId IdType="pmc">PMC7605520</ArticleId><ArticleId IdType="pubmed">32937615</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemis V., Schmidt T., Schub D., Mihm J., Marx S., Abu-Omar A., Ziegler L., Hielscher F., Guckelmus C., Urschel R., et al. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nat. Commun. 2022;13:4710. doi: 10.1038/s41467-022-32321-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32321-0</ArticleId><ArticleId IdType="pmc">PMC9366133</ArticleId><ArticleId IdType="pubmed">35953492</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt T., Klemis V., Schub D., Mihm J., Hielscher F., Marx S., Abu-Omar A., Ziegler L., Guckelmus C., Urschel R., et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat. Med. 2021;27:1530&#x2013;1535. doi: 10.1038/s41591-021-01464-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01464-w</ArticleId><ArticleId IdType="pmc">PMC8440177</ArticleId><ArticleId IdType="pubmed">34312554</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt T., Sester M. Detection of antigen-specific T cells based on intracellular cytokine staining using flow-cytometry. Methods Mol. Biol. 2013;1064:267&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">23996264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsur A., Furer A., Avramovich E., Karp E., Twig G., Bader T., Almakias M., Fink N. SARS-CoV-2 Epidemic in the Israeli Defense Force-Lessons Learned from Our rt-PCR Screening Policy. Mil. Med. 2021;188:e65&#x2013;e68. doi: 10.1093/milmed/usab215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/milmed/usab215</ArticleId><ArticleId IdType="pmc">PMC8194723</ArticleId><ArticleId IdType="pubmed">34027977</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt T., Klemis V., Schub D., Schneitler S., Reichert M.C., Wilkens H., Sester U., Sester M., Mihm J. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am. J. Transplant. 2021;21:3990&#x2013;4002. doi: 10.1111/ajt.16818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16818</ArticleId><ArticleId IdType="pmc">PMC8652989</ArticleId><ArticleId IdType="pubmed">34453872</ArticleId></ArticleIdList></Reference><Reference><Citation>Hielscher F., Schmidt T., Klemis V., Wilhelm A., Marx S., Abu-Omar A., Ziegler L., Guckelmus C., Urschel R., Sester U., et al. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens. J. Clin. Virol. 2022;157:105321. doi: 10.1016/j.jcv.2022.105321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105321</ArticleId><ArticleId IdType="pmc">PMC9576915</ArticleId><ArticleId IdType="pubmed">36279695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M., Worlock K.B., Huang N., Lindeboom R.G.H., Butler C.R., Kumasaka N., Conde C.D., Mamanova L., Bolt L., Richardson L., et al. Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature. 2022;602:321&#x2013;327. doi: 10.1038/s41586-021-04345-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04345-x</ArticleId><ArticleId IdType="pmc">PMC8828466</ArticleId><ArticleId IdType="pubmed">34937051</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell A.C., Butler M.S., Jinks E., Tut G., Lancaster T., Sylla P., Begum J., Bruton R., Pearce H., Verma K., et al. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nat. Immunol. 2022;23:40&#x2013;49. doi: 10.1038/s41590-021-01089-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01089-8</ArticleId><ArticleId IdType="pmc">PMC8709786</ArticleId><ArticleId IdType="pubmed">34937928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lineburg K.E., Grant E.J., Swaminathan S., Chatzileontiadou D.S.M., Szeto C., Sloane H., Panikkar A., Raju J., Crooks P., Rehan S., et al. CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity. 2021;54:1055&#x2013;1065.e1055. doi: 10.1016/j.immuni.2021.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.04.006</ArticleId><ArticleId IdType="pmc">PMC8043652</ArticleId><ArticleId IdType="pubmed">33945786</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y.J., Okuda K., Edwards C.E., Martinez D.R., Asakura T., Dinnon K.H., 3rd, Kato T., Lee R.E., Yount B.L., Mascenik T.M., et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020;182:429&#x2013;446.e414. doi: 10.1016/j.cell.2020.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.042</ArticleId><ArticleId IdType="pmc">PMC7250779</ArticleId><ArticleId IdType="pubmed">32526206</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang G., Bushman F.D. The human virome: Assembly, composition and host interactions. Nat. Rev. Microbiol. 2021;19:514&#x2013;527. doi: 10.1038/s41579-021-00536-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00536-5</ArticleId><ArticleId IdType="pmc">PMC8008777</ArticleId><ArticleId IdType="pubmed">33785903</ArticleId></ArticleIdList></Reference><Reference><Citation>Pride D.T., Salzman J., Haynes M., Rohwer F., Davis-Long C., White R.A., 3rd, Loomer P., Armitage G.C., Relman D.A. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. ISME J. 2012;6:915&#x2013;926. doi: 10.1038/ismej.2011.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2011.169</ArticleId><ArticleId IdType="pmc">PMC3329113</ArticleId><ArticleId IdType="pubmed">22158393</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopala S.V., Bakhoum N.G., Pakala S.B., Shilts M.H., Rosas-Salazar C., Mai A., Boone H.H., McHenry R., Yooseph S., Halasa N., et al. Metatranscriptomics to characterize respiratory virome, microbiome, and host response directly from clinical samples. Cell Rep. Methods. 2021;1:100091. doi: 10.1016/j.crmeth.2021.100091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crmeth.2021.100091</ArticleId><ArticleId IdType="pmc">PMC8594859</ArticleId><ArticleId IdType="pubmed">34790908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan S.C. Innate and adaptive immune responses to SARS-CoV-2 in humans: Relevance to acquired immunity and vaccine responses. Clin. Exp. Immunol. 2021;204:310&#x2013;320. doi: 10.1111/cei.13582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13582</ArticleId><ArticleId IdType="pmc">PMC8013613</ArticleId><ArticleId IdType="pubmed">33534923</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia W.N., Zhu F., Ong S.W.X., Young B.E., Fong S.W., Le Bert N., Tan C.W., Tiu C., Zhang J., Tan S.Y., et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: A longitudinal study. Lancet Microbe. 2021;2:e240&#x2013;e249. doi: 10.1016/S2666-5247(21)00025-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00025-2</ArticleId><ArticleId IdType="pmc">PMC7987301</ArticleId><ArticleId IdType="pubmed">33778792</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Chen D., Yuan D., Lausted C., Choi J., Dai C.L., Voillet V., Duvvuri V.R., Scherler K., Troisch P., et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183:1479&#x2013;1495.e1420. doi: 10.1016/j.cell.2020.10.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.037</ArticleId><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer B., Knoll R., Bonaguro L., ToVinh M., Raabe J., Astaburuaga-Garcia R., Schulte-Schrepping J., Kaiser K.M., Rieke G.J., Bischoff J., et al. Early IFN-alpha signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021;54:2650&#x2013;2669.e2614. doi: 10.1016/j.immuni.2021.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8416549</ArticleId><ArticleId IdType="pubmed">34592166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.W., Su Y., Baloni P., Chen D., Pavlovitch-Bedzyk A.J., Yuan D., Duvvuri V.R., Ng R.H., Choi J., Xie J., et al. Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19. Nat. Biotechnol. 2022;40:110&#x2013;120. doi: 10.1038/s41587-021-01020-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-01020-4</ArticleId><ArticleId IdType="pmc">PMC9206886</ArticleId><ArticleId IdType="pubmed">34489601</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Zaslavsky M., Su Y., Guo J., Sikora M.J., van Unen V., Christophersen A., Chiou S.-H., Chen L., Li J., et al. KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Science. 2022;376:eabi9591. doi: 10.1126/science.abi9591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi9591</ArticleId><ArticleId IdType="pmc">PMC8995031</ArticleId><ArticleId IdType="pubmed">35258337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>